Beijixi Liquid Wart Corn Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, presenting as tender to touch and exhibiting an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is important to allow the application to dry fully. This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, use is contraindicated in patients with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only; it is imperative to keep the product away from fire and flame to prevent potential hazards.

General precautions must be observed to ensure safe application. The product should not be used on irritated skin or any area that is infected or reddened. It is contraindicated for application on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Additionally, individuals with diabetes or poor blood circulation should avoid using this product.

In the event of accidental ingestion, immediate medical assistance is required. Healthcare professionals should advise patients to contact the Poison Control Center at 1-800-222-1222 without delay.

Patients should be instructed to discontinue use and consult a physician if discomfort persists, ensuring that any adverse reactions are appropriately addressed.

Side Effects

Patients should be aware that the product is for external use only and should be kept away from fire and flame to prevent any potential hazards.

In the event that discomfort persists, it is advised that patients stop using the product and consult a healthcare professional. This recommendation is crucial to ensure safety and address any underlying issues that may arise during use.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Beijixi Liquid Wart Corn Remover (salicylic acid 17% liquid wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The available prescribing information does not provide specific data regarding the use of this product during pregnancy. Consequently, there are no established safety concerns, dosage modifications, or special precautions outlined for pregnant patients. Healthcare professionals should exercise caution when prescribing this product to women of childbearing potential and consider the lack of information when assessing the potential risks and benefits for pregnant patients. It is advisable to monitor any emerging data related to fetal outcomes as it becomes available.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, no data are provided concerning the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential. If symptoms of overdosage are observed, appropriate interventions should be implemented based on the patient's condition.

Healthcare professionals should also consider contacting a poison control center or a medical toxicologist for guidance on management strategies tailored to the specific situation. Documentation of the incident and any interventions performed is crucial for ongoing patient care and safety.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed.

Patients should be informed about the importance of avoiding contact with the eyes. In the event that the product comes into contact with the eyes, they should flush the eyes with water for at least 15 minutes and seek medical attention if irritation persists.

It is essential to emphasize that the product is non-edible. Patients should be instructed to keep the product tightly capped and stored at room temperature, away from heat sources, to ensure safety and efficacy.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that the temperature does not exceed 37°C (99°F) to avoid excessive heat exposure. Proper storage conditions are essential to maintain the integrity of the product.

Additional Clinical Information

The medication is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Beijixi Liquid Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)